Special Offering :
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
The Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market size is expected to reach $1,180.7 million by 2024, rising at a market growth of 30.4% CAGR during the forecast period. Glaucoma is a progressive disease and is the major cause of irreversible blindness with an estimated burden to rise 111.8 million by 2040. This has increased the demand for MIGS devices in the treatment of glaucoma. Minimally Invasive Glaucoma Surgery has emerged out to be a novel prospect in the treatment of glaucoma and have been touted safer and quicker recovery compared to traditional means has contributed to the significant demand for these devices globally.
The advent of MIGS devices recently has revolutionized the patients care with any condition of glaucoma alone or in conjunction with cataract. The factors driving the market include rapid rise in geriatric population, who are more prone to ophthalmology diseases such as glaucoma and cataract. The novel paradigm of glaucoma therapy by using MIGS devices will aspire to a much reduced dependence on topical medication. In addition, increasing preference of surgeons for MIGS is adding boost to the market growth.
On the basis of Surgery, the market is segmented into Glaucoma in Conjunction with Cataract and Stand Alone Glaucoma. Target is categorized into Trabecular Meshwork, Suprachoroidal Space and Other Targets. On the basis of Product, the market is segmented into MIGS Stents, MIGS Shunts and Other Products. The End Users covered under the report are Eye Hospitals, Ophthalmology Clinics and Others. Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa (LAMEA).
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Prominent players offering minimally invasive glaucoma surgery (MIGS) devices include Ellex Medical Lasers Ltd, Allergan Plc, Santen Pharmaceutical Co., Ltd., Glaukos Corporation, Alcon Inc. (Novartis), Lumenis, Ivantis, Inc., iSTAR Medical, InnFocus Inc., and SOLX, Inc.